Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:33 PM
Ignite Modification Date:
2025-12-24 @ 6:33 PM
NCT ID:
NCT03011957
Eligibility Criteria:
Inclusion Criteria:
Group 1: HIV positive subjects
* HIV positive
* English speaking
* 50-65 years old
* On Antiretroviral therapy and an HIV viral load below 200 copies/ml
* CD4 equal to or greater than 350 cells/mm3
* Postmenopausal (women)
* Lower extremity mobility sufficient to participate in functional assessment.
Group 2: HIV negative subjects Inclusion Criteria for Group 2 subjects
* English speaking
* 50-65 years old
* Negative for HIV (based on an HIV antibody test at Study Visit 1)
* Matched to Group 1 for sex (50% W, 50% M) and age (50 - 65yo)
* Postmenopausal (women)
* Lower extremity mobility sufficient to participate in functional assessment.
Exclusion Criteria:
Exclusion Criteria for Group 1 Subjects
* Acute or serious illness within 60 days prior to entry
* Use of pharmacologic doses of corticosteroids in the past 6 months.
* Use of anabolic therapy in the past 6 months.
* Lower extremity mobility insufficient to participate in functional assessment.
* Current use (last 30 days) of anticoagulants or known bleeding disorder.
Exclusion Criteria for Group 2 subjects
* Acute or serious illness within 60 days prior to entry
* Use of pharmacologic doses of corticosteroids in the past 6 months
* Use of anabolic therapy in the past 6 months
* Lower extremity mobility insufficient to participate in functional assessment
* Current use (last 30 days) of anticoagulants or known bleeding disorder.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
50 Years
Maximum Age:
65 Years
Study:
NCT03011957
Study Brief:
Protocol Section:
NCT03011957